Last reviewed · How we verify
Linzess
At a glance
| Generic name | Linzess |
|---|---|
| Also known as | Linaclotide |
| Sponsor | TriHealth Inc. |
| Target | Heat-stable enterotoxin receptor, Heat-stable enterotoxin receptor |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | discontinued |
Approved indications
- Chronic idiopathic constipation
- Irritable bowel syndrome
- Irritable bowel syndrome characterized by constipation
Common side effects
Key clinical trials
- Investigation of Linaclotide's Effect on the Bi-directional Brain and Gut Axis in IBS-C Patients (NA)
- Phase II Randomized, Placebo-Controlled Trial of Linaclotide to Demonstrate Bioactivity in Patients With Sporadic Colorectal Adenomas and With Colorectal Cancer (Phase 2)
- A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial of Linaclotide Administered Orally for 12 Weeks in Patients With Chronic Constipation (Phase 3)
- An Open-Label, Long-Term Safety Study of Oral Linaclotide Administered to Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation (Phase 3)
- Assessment of Responsiveness to Treatment of the Experience Sampling Method (ESM) in Irritable Bowel Syndrome (IBS) Using Linaclotide (N/A)
- Efficacy of Linaclotide in Type II Diabetics With Chronic Constipation: A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Trial (Phase 4)
- Clinical Study on the Application of Lactulose Combined with Linaclotide in Bowel Preparation for Colonoscopy (Phase 4)
- Phase III Study of ASP0456 - A Double-blind, Placebo-controlled, Parallel-group, Comparative Study and Long-term Study in Patients With Irritable Bowel Syndrome With Constipation (IBS-C) (Phase 3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Linzess CI brief — competitive landscape report
- Linzess updates RSS · CI watch RSS
- TriHealth Inc. portfolio CI